Table 3.
Adjusted* mean (SE) percent change from baseline to follow-up time by randomization arm, overall and stratified by gender
| Outcome (% Change from Baseline) |
Year 8 | LA extension | Yr 8 to LA-E ILI vs DSE |
|||||
|---|---|---|---|---|---|---|---|---|
| ILI | DSE | p-value | ILI | DSE | p-value | p-value | ||
| Overall | Total Hip BMD | -4.3 (0.36) | -3.7 (0.35) | 0.1538 | -6.3 (0.42) | -5.4 (0.41) | 0.0600 | 0.4724 |
| Femoral Neck BMD | -4.8 (0.46) | -3.5 (0.45) | 0.0122 | -6.8 (0.54) | -6.5 (0.54) | 0.6003 | 0.2106 | |
| Lumbar Spine BMD | 1.9 (0.41) | 1.4 (0.40) | 0.2423 | 4.0 (0.47) | 4.4 (0.46) | 0.4595 | 0.1186 | |
| Whole Body BMD | 0.77 (0.36) | 1.3 (0.35) | 0.1861 | -0.77 (0.42) | 0.71 (0.42) | 0.0029 | 0.0788 | |
| Men | Total Hip BMD | -2.7 (0.69) | -1.6 (0.67) | 0.0263 | -2.5 (0.75) | -0.73 (0.73) | 0.0062 | 0.3471 |
| Femoral Neck BMD | -3.5 (1.08) | -2.1 (1.04) | 0.0951 | -3.0 (1.19) | -3.1 (1.16) | 0.9459 | 0.2494 | |
| Lumbar Spine BMD | 5.3 (0.98) | 5.1 (0.94) | 0.7603 | 9.8 (1.04) | 10.1 (1.00) | 0.7040 | 0.5421 | |
| Whole Body BMD | 2.7 (0.76) | 3.4 (0.73) | 0.2029 | 1.7 (0.83) | 4.6 (0.80) | < .0001 | 0.0060 | |
| Women | Total Hip BMD | -6.1 (0.46) | -6.0 (0.45) | 0.8034 | -9.5 (0.53) | -9.4 (0.54) | 0.7796 | 0.9359 |
| Femoral Neck BMD | -6.5 (0.55) | -5.4 (0.54) | 0.0735 | -10.2 (0.64) | -9.9 (0.65) | 0.6377 | 0.3704 | |
| Lumbar Spine BMD | -0.89 (0.48) | -1.7 (0.48) | 0.1237 | -0.28 (0.56) | -0.23 (0.56) | 0.9409 | 0.2162 | |
| Whole Body BMD | -0.85 (0.45) | -0.60 (0.45) | 0.6311 | -2.7 (0.53) | -2.5 (0.54) | 0.7186 | 0.9887 | |
*Adjusted for repeated measures, age, race/ethnicity, study site, baseline total mass, taking bone-positive
medications at baseline, taking bone-negative medications at baseline, and the baseline value of the outcome
Overall models also adjust for gender